Avidity Biosciences to Participate in Upcoming Investor Conferences
Avidity Biosciences (Nasdaq: RNA), a biopharmaceutical company developing Antibody Oligonucleotide Conjugates (AOCs™), has announced its participation in two upcoming investor conferences. The company will present at the Wells Fargo 2024 Healthcare Conference on September 4 at 5:00 a.m. PT / 8:00 a.m. ET and the Cantor Global Healthcare Conference on September 17 at 6:45 a.m. PT / 9:45 a.m. ET.
Investors and interested parties can access live webcasts and archived replays of both events through the 'Events and Presentations' page in the 'Investors' section of Avidity's website. This participation in major healthcare conferences demonstrates Avidity's commitment to engaging with investors and showcasing its progress in developing innovative RNA therapeutics.
Avidity Biosciences (Nasdaq: RNA), un'azienda biofarmaceutica che sviluppa conjugati di oligonucleotidi con anticorpi (AOCs™), ha annunciato la propria partecipazione a due prossime conferenze per investitori. L'azienda presenterà alla Wells Fargo 2024 Healthcare Conference il 4 settembre alle 5:00 PT / 8:00 ET e alla Cantor Global Healthcare Conference il 17 settembre alle 6:45 PT / 9:45 ET.
Gli investitori e le parti interessate possono accedere alle dirette web e alle registrazioni archiviate di entrambi gli eventi attraverso la pagina 'Eventi e Presentazioni' nella sezione 'Investitori' del sito web di Avidity. Questa partecipazione a importanti conferenze nel settore della salute dimostra l'impegno di Avidity nel coinvolgere gli investitori e nel mettere in mostra i propri progressi nello sviluppo di terapie innovative a base di RNA.
Avidity Biosciences (Nasdaq: RNA), una empresa biofarmacéutica que desarrolla conjugados de oligonucleótidos con anticuerpos (AOCs™), ha anunciado su participación en dos próximas conferencias para inversionistas. La empresa presentará en la C conferencia de Salud 2024 de Wells Fargo el 4 de septiembre a las 5:00 a.m. PT / 8:00 a.m. ET y en la C conferencia Global de Salud de Cantor el 17 de septiembre a las 6:45 a.m. PT / 9:45 a.m. ET.
Los inversionistas y partes interesadas pueden acceder a las transmisiones web en vivo y a las repeticiones archivadas de ambos eventos a través de la página de 'Eventos y Presentaciones' en la sección de 'Inversionistas' del sitio web de Avidity. Esta participación en importantes conferencias de salud demuestra el compromiso de Avidity de interactuar con los inversionistas y mostrar su progreso en el desarrollo de terapias innovadoras basadas en RNA.
Avidity Biosciences (Nasdaq: RNA)는 항체 올리고뉴클레오타이드 접합체(AOCs™)를 개발하는 생명공학 회사로, 두 개의 다가오는 투자자 회의에 참여한다고 발표했습니다. 이 회사는 웰스 파고 2024 헬스케어 컨퍼런스에서 9월 4일 오전 5:00 PT / 오전 8:00 ET에 발표하고, 칸토 글로벌 헬스케어 컨퍼런스에서 9월 17일 오전 6:45 PT / 오전 9:45 ET에 발표할 예정입니다.
투자자 및 관심 있는 분들은 Avidity 웹사이트의 '투자자' 섹션에 있는 '이벤트 및 발표' 페이지를 통해 두 이벤트의 실시간 웹캐스트 및 아카이브 재생에 접근할 수 있습니다. 이러한 주요 헬스케어 컨퍼런스에의 참여는 Avidity가 투자자와 소통하고 혁신적인 RNA 치료제 개발의 진전을 뒷받침하려는 노력을 보여줍니다.
Avidity Biosciences (Nasdaq: RNA), une société biopharmaceutique développant des conjugués d'oligonucleotides anticorps (AOCs™), a annoncé sa participation à deux prochaines conférences pour investisseurs. La société présentera à la Wells Fargo 2024 Healthcare Conference le 4 septembre à 5h00 PT / 8h00 ET et à la Cantor Global Healthcare Conference le 17 septembre à 6h45 PT / 9h45 ET.
Les investisseurs et les parties intéressées peuvent accéder aux webcasts en direct et aux rediffusions archivées des deux événements via la page 'Événements et Présentations' dans la section 'Investisseurs' du site web d'Avidity. Cette participation à des conférences majeures dans le secteur de la santé démontre l'engagement d'Avidity à dialoguer avec les investisseurs et à mettre en avant ses progrès dans le développement de thérapies innovantes à base d'ARN.
Avidity Biosciences (Nasdaq: RNA), ein biopharmazeutisches Unternehmen, das Antikörper-Oligonukleotid-Konjugate (AOCs™) entwickelt, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen bekannt gegeben. Das Unternehmen wird am Wells Fargo 2024 Healthcare Conference am 4. September um 5:00 Uhr PT / 8:00 Uhr ET und an der Cantor Global Healthcare Conference am 17. September um 6:45 Uhr PT / 9:45 Uhr ET präsentieren.
Investoren und Interessierte können über die Seite 'Events and Presentations' im Bereich 'Investoren' der Avidity-Website auf Live-Webcasts und archivierte Wiederholungen beider Veranstaltungen zugreifen. Diese Teilnahme an großen Gesundheitskonferenzen zeigt Aviditys Engagement für den Austausch mit Investoren und die Präsentation seiner Fortschritte bei der Entwicklung innovativer RNA-Therapeutika.
- None.
- None.
- Wells Fargo 2024 Healthcare Conference on September 4 at 5:00 a.m. PT / 8:00 a.m. ET
- Cantor Global Healthcare Conference on September 17 at 6:45 a.m. PT / 9:45 a.m. ET
A live webcast of both events, up-to-date event details and archived replays will be available on the "Events and Presentations" page in the "Investors" section of Avidity's website at https://aviditybiosciences.investorroom.com/events-and-presentations.
About Avidity
Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through internal discovery efforts and key partnerships. Avidity is headquartered in
Investor Contact:
Mike MacLean
(619) 837-5014
investors@aviditybio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-to-participate-in-upcoming-investor-conferences-302230787.html
SOURCE Avidity Biosciences, Inc.
FAQ
When is Avidity Biosciences (RNA) presenting at the Wells Fargo 2024 Healthcare Conference?
What time is Avidity Biosciences (RNA) speaking at the Cantor Global Healthcare Conference?
How can investors access Avidity Biosciences' (RNA) conference presentations?
What type of RNA therapeutics is Avidity Biosciences (RNA) developing?
